Danish Commercial Services Stock News

In November 2025, Novo Nordisk announced that its Evoke and Evoke+ phase 3 trials found oral semaglutide did not significantly slow progression in early-stage Alzheimer's disease, prompting the company to discontinue a planned extension of the studies. This outcome marks a setback in the company's efforts to expand GLP-1-based medicines beyond diabetes and obesity into neurology, highlighting the challenges of diversifying its drug pipeline while facing increased competition in core...

Rockwool (CPSE:ROCK B) has just released its Q3 2025 results, reporting revenue of €963 million and basic EPS of €0.6, with net income (excluding extra items) at €122 million. Looking back, the company has seen revenues move from €957 million in Q3 2024 through varying quarters to €963 million this quarter. EPS has ranged between €0.54 and €0.7 per share across recent results. Margins settled somewhat from last year's levels, reflecting steady but less dynamic profitability as investors weigh...

Curious if Genmab is a bargain right now? Let’s dive into what might make this innovative biotech stock an appealing buy, or a candidate for caution. After an impressive 32.5% rally year-to-date and a 34.3% jump over the last 12 months, Genmab’s stock has been firmly in the spotlight, suggesting renewed investor optimism. Several partnership announcements and drug development milestones have fueled Genmab’s price momentum recently, with news flow focused on promising pipeline progress and...

With a price-to-earnings (or "P/E") ratio of 17.5x Demant A/S ( CPH:DEMANT ) may be sending bearish signals at the...

Vestas Wind Systems A/S ( CPH:VWS ) shares have had a really impressive month, gaining 25% after a shaky period...

Key Insights Ambu's Annual General Meeting to take place on 3rd of December Salary of kr.8.01m is part of CEO Britt...

Amid renewed concerns over inflated AI stock valuations and receding expectations for a U.S. interest rate cut, European markets have experienced a downturn, with major indexes such as the STOXX Europe 600 and Germany's DAX seeing notable declines. In this environment of cautious sentiment, identifying undervalued stocks can present opportunities for investors seeking value in solid fundamentals and potential for growth despite broader market challenges.

Nilfisk Holding A/S ( CPH:NLFSK ) just released its latest quarterly report and things are not looking great. It was a...

The cBrain A/S ( CPH:CBRAIN ) share price has fared very poorly over the last month, falling by a substantial 28%. The...

H. Lundbeck A/S ( CPH:HLUN B ) just reported healthy earnings but the stock price didn't move much. Our analysis...

Some FLSmidth & Co. A/S ( CPH:FLS ) shareholders may be a little concerned to see that the Group Chief Executive...

Earlier in November 2025, Scandinavian Tobacco Group A/S reported third quarter and nine-month results, revealing declines in both sales and net income compared to the prior year, and announced a narrowing of its full-year earnings guidance due to factors such as US consumer sentiment and currency fluctuations. The company highlighted that US retailer inventory decisions and changes in the USD/DKK exchange rate continue to create meaningful uncertainty for its full-year outlook. We'll...

A.P. Møller Mærsk (CPSE:MAERSK B) shares have edged slightly higher today, continuing a fairly steady performance in recent sessions. Investors are watching the logistics giant’s moves closely, especially given recent shifts in the wider shipping industry. See our latest analysis for A.P. Møller - Mærsk. After a muted start to the year, A.P. Møller - Mærsk has held its ground amidst industry shifts, with its latest share price at DKK 12,550. While short-term share price returns have been...

Zealand Pharma (CPSE:ZEAL) just released its third quarter and nine-month results for 2025, showing a dramatic turnaround in both sales and profitability compared to the same periods last year. Investor attention is clearly focused on this shift. See our latest analysis for Zealand Pharma. After a tough start to the year, Zealand Pharma’s third quarter results have injected new optimism into the stock, with momentum clearly picking up as shown by the 24% share price return over the last 90...

Danske Bank has commenced a substantial share buy-back programme of up to DKK 5 billion, executing purchases of 211,000 shares on Nasdaq Copenhagen in the past week, which represents 1.849% of its share capital to date. Share buy-back programmes of this scale can often reflect management’s confidence in the company’s fundamentals and contribute to improving earnings per share through reduced share count. We’ll explore how Danske Bank’s active share repurchases could influence its investment...

Despite TORM plc's ( CPH:TRMD A ) recent earnings report having lackluster headline numbers, the market responded...

Shareholders appeared unconcerned with Solar A/S' ( CPH:SOLAR B ) lackluster earnings report last week. We did some...

Zealand Pharma A/S ( CPH:ZEAL ) just released its latest third-quarter results and things are looking bullish. Revenue...

Vestas Wind Systems recently reported strong third-quarter earnings, with net income rising to €302 million and sales of €5.34 billion, alongside announcing new wind turbine orders totaling 547 MW across North America and Germany. The combination of improved profitability and significant order intake highlights continued momentum in both Vestas’s financial performance and market demand for its renewable energy solutions. We'll examine how these robust new orders and improved quarterly...

It's been a pretty great week for ALK-Abelló A/S ( CPH:ALK B ) shareholders, with its shares surging 15% to kr.230 in...

Last week, you might have seen that Matas A/S ( CPH:MATAS ) released its quarterly result to the market. The early...

Wondering if Ørsted's recent turbulence means the stock is a hidden bargain or a value trap? You're not alone, and the story behind the numbers is surprisingly layered. After years of struggles, Ørsted’s stock has rebounded 5.4% over the past week and 2.7% in the last 30 days, yet it is still down a striking 63.1% year-to-date and 43.3% over the past year. Recent headlines have centered around Ørsted’s abrupt project cancellations and the company’s ongoing efforts to stabilize its offshore...

Embla Medical has opened a new prosthetic clinic in Kyiv and, at the opening, announced a three-year partnership with the Government of Iceland to deliver prosthetic care and rehabilitation to up to 1,000 Ukrainian amputees, with a total program value of US$11 million co-financed by both parties and supported by Future for Ukraine. This initiative directly addresses Ukraine’s unprecedented need for advanced prosthetic support following the war, highlighting Embla Medical’s commitment to...

FLSmidth (CPSE:FLS) shares have moved slightly higher, trading near DKK 434. Investors are likely watching recent performance and shifting sentiment as the company continues to navigate a challenging industrial landscape in Denmark this month. See our latest analysis for FLSmidth. With FLSmidth’s share price gaining over 20% year-to-date and the one-year total shareholder return above 18%, momentum has stayed firmly positive, even after a recent short-term dip. The stock’s formidable 121%...